Extracellular Vesicles and Resistance to Anticancer Drugs: A Tumor Skeleton Key for Unhinging Chemotherapies.
chemoresistance
extracellular vesicles
metastasis
tumor microenvironment
tumor recurrence
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
05
2022
accepted:
20
05
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
Although surgical procedures and clinical care allow reaching high success in fighting most tumors, cancer is still a formidable foe. Recurrence and metastatization dampen the patients' overall survival after the first diagnosis; nevertheless, the large knowledge of the molecular bases drives these aspects. Chemoresistance is tightly linked to these features and is mainly responsible for the failure of cancer eradication, leaving patients without a crucial medical strategy. Many pathways have been elucidated to trigger insensitiveness to drugs, generally associated with the promotion of tumor growth, aggressiveness, and metastatisation. The main mechanisms reported are the expression of transporter proteins, the induction or mutations of oncogenes and transcription factors, the alteration in genomic or mitochondrial DNA, the triggering of autophagy or epithelial-to-mesenchymal transition, the acquisition of a stem phenotype, and the activation of tumor microenvironment cells.
Identifiants
pubmed: 35814444
doi: 10.3389/fonc.2022.933675
pmc: PMC9259994
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
933675Informations de copyright
Copyright © 2022 Pompili, Vetuschi, Sferra and Cappariello.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Cancer Res. 2014 Oct;12(10):1377-87
pubmed: 24874432
Trends Cancer. 2020 Jan;6(1):20-30
pubmed: 31952777
Anticancer Res. 2005 Nov-Dec;25(6A):3703-7
pubmed: 16302729
Oncol Rep. 2016 Mar;35(3):1664-70
pubmed: 26752104
Int J Biol Sci. 2018 Nov 1;14(14):1960-1973
pubmed: 30585260
J Virol. 2013 Sep;87(18):10334-47
pubmed: 23864627
Oncogene. 2017 Aug;36(31):4457-4468
pubmed: 28368410
J Extracell Vesicles. 2021 Dec;10(14):e12144
pubmed: 34919343
Int J Mol Sci. 2021 Jul 06;22(14):
pubmed: 34298894
J Proteome Res. 2008 Dec;7(12):5157-66
pubmed: 19367702
Cancer Res. 2017 Apr 15;77(8):2134-2147
pubmed: 28202523
Evid Based Complement Alternat Med. 2020 Sep 17;2020:8394574
pubmed: 33014113
J Extracell Vesicles. 2019 Nov 15;8(1):1690217
pubmed: 31819794
Cell. 2001 Jul 27;106(2):145-55
pubmed: 11511343
Nat Rev Cancer. 2004 Nov;4(11):839-49
pubmed: 15516957
Cell Stem Cell. 2014 Mar 6;14(3):342-56
pubmed: 24607406
Cell Mol Life Sci. 2019 Nov;76(21):4203-4219
pubmed: 31300868
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Oncogene. 2004 Mar 25;23(13):2330-8
pubmed: 14743206
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Nat Med. 2001 Sep;7(9):1028-34
pubmed: 11533706
Sci Rep. 2020 May 19;10(1):8271
pubmed: 32427870
Oncotarget. 2016 Aug 2;7(31):50365-50379
pubmed: 27391262
Mol Biol Cell. 2014 Sep 15;25(18):2677-81
pubmed: 25213191
Nat Med. 1995 Jun;1(6):578-82
pubmed: 7585126
J Cell Sci. 2011 Feb 1;124(Pt 3):447-58
pubmed: 21242314
Exp Mol Med. 2020 Nov;52(11):1809-1822
pubmed: 33144675
J Exp Clin Cancer Res. 2018 Mar 12;37(1):52
pubmed: 29530052
Curr Biol. 2009 Dec 1;19(22):1875-85
pubmed: 19896381
Cancers (Basel). 2019 Aug 20;11(8):
pubmed: 31434275
Acta Med Okayama. 2018 Apr;72(2):165-174
pubmed: 29674765
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70
pubmed: 9861027
Acta Oncol. 2009;48(8):1173-80
pubmed: 19863226
Biol Chem. 1999 Jul-Aug;380(7-8):879-87
pubmed: 10494837
Cancer Res. 1995 Oct 1;55(19):4214-9
pubmed: 7671223
J Cancer. 2020 Oct 18;11(24):7116-7126
pubmed: 33193874
Science. 2008 Feb 29;319(5867):1244-7
pubmed: 18309083
Neurosurgery. 2018 Sep 1;83(3):E98-E100
pubmed: 30125027
Cancer Cell Int. 2021 May 1;21(1):245
pubmed: 33933069
FEBS Lett. 2006 Feb 13;580(4):1103-11
pubmed: 16387301
Biomed Pharmacother. 2022 May;149:112810
pubmed: 35303564
Carbohydr Polym. 2018 Dec 15;202:323-333
pubmed: 30287007
Nat Aging. 2021 Dec;1(12):1148-1161
pubmed: 35665306
Stem Cells. 2009 Dec;27(12):2875-83
pubmed: 19816957
Oncotarget. 2015 Apr 20;6(11):9313-26
pubmed: 25823654
Oncotarget. 2015 Mar 30;6(9):7000-10
pubmed: 25760076
Annu Rev Pharmacol Toxicol. 2016;56:85-102
pubmed: 26514196
Ann N Y Acad Sci. 2010 Jul;1201:34-9
pubmed: 20649536
Mol Cell Biol. 2001 Nov;21(22):7817-25
pubmed: 11604516
Diagnostics (Basel). 2022 Mar 08;12(3):
pubmed: 35328212
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Theranostics. 2018 Jun 24;8(14):3932-3948
pubmed: 30083271
Int J Oncol. 2016 Jul;49(1):189-96
pubmed: 27176642
Nat Rev Mol Cell Biol. 2020 Oct;21(10):585-606
pubmed: 32457507
Front Cell Dev Biol. 2021 Dec 13;9:791882
pubmed: 34966744
J Biol Chem. 2009 Dec 4;284(49):34211-22
pubmed: 19801663
Cancer Lett. 2017 Oct 10;406:12-21
pubmed: 28778566
PLoS One. 2015 Mar 30;10(3):e0122308
pubmed: 25822260
PLoS One. 2012;7(4):e35487
pubmed: 22530032
Oncotarget. 2017 Jul 6;8(35):59950-59964
pubmed: 28938696
Br J Cancer. 2019 Jul;121(2):157-171
pubmed: 31239543
Tumour Biol. 2014 Nov;35(11):10773-9
pubmed: 25077924
Cells. 2020 Apr 26;9(5):
pubmed: 32357574
Int J Mol Sci. 2019 Sep 27;20(19):
pubmed: 31569680
J Clin Invest. 2006 Jul;116(7):1955-62
pubmed: 16794736
Eur J Pharmacol. 2013 Dec 5;721(1-3):116-25
pubmed: 24095666
Dig Liver Dis. 2009 Dec;41(12):875-80
pubmed: 19473897
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Braz J Med Biol Res. 2017 Nov 13;51(1):e6472
pubmed: 29160412
Nat Commun. 2015 Jun 15;6:7439
pubmed: 26074490
Drug Metab Dispos. 2018 Mar;46(3):292-302
pubmed: 29311138
Eur J Histochem. 2017 May 16;61(2):2732
pubmed: 28735518
Dalton Trans. 2018 May 15;47(19):6645-6653
pubmed: 29632935
J Exp Med. 2013 Dec 16;210(13):2851-72
pubmed: 24323355
Curr Med Chem. 2018;25(29):3414-3434
pubmed: 29521203
Mitochondrion. 2014 May;16:55-64
pubmed: 24177748
Cell Biol Int. 2021 Apr;45(4):858-868
pubmed: 33325136
Mol Cancer. 2019 May 7;18(1):91
pubmed: 31064356
Mol Med Rep. 2015 Jul;12(1):192-8
pubmed: 25684678
Front Oncol. 2021 Nov 18;11:769036
pubmed: 34868997
Bone. 2021 Dec;153:116130
pubmed: 34329816
Int J Mol Sci. 2020 Nov 17;21(22):
pubmed: 33213099
Genes Cancer. 2013 Jul;4(7-8):261-72
pubmed: 24167654
Oncogene. 2007 Feb 8;26(6):851-8
pubmed: 16878148
Drug Metab Dispos. 2008 Dec;36(12):2571-81
pubmed: 18775981
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160-4
pubmed: 1976252
Blood. 2014 Jul 24;124(4):555-66
pubmed: 24928860
J Biomed Biotechnol. 2012;2012:170325
pubmed: 22911014
Mol Carcinog. 2016 Sep;55(9):1329-42
pubmed: 26293643
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
J Cell Sci. 2013 Dec 15;126(Pt 24):5553-65
pubmed: 24105262
Nanomedicine. 2018 Jan;14(1):195-204
pubmed: 28982587
Oncogene. 2002 Mar 7;21(11):1641-8
pubmed: 11896595
Oncol Lett. 2018 Feb;15(2):2039-2048
pubmed: 29434903
J Ovarian Res. 2021 Jun 21;14(1):80
pubmed: 34148553
PLoS One. 2014 Sep 22;9(9):e107109
pubmed: 25243473
PLoS One. 2012;7(10):e46737
pubmed: 23091600
Nutrition. 2022 Feb;94:111511
pubmed: 34813981
Mol Oncol. 2016 Aug;10(7):1008-29
pubmed: 27118659
Cancer Lett. 2017 Dec 28;411:117-129
pubmed: 28987388
Oncol Rep. 2015 Sep;34(3):1460-8
pubmed: 26165320
Oncogene. 2012 May 10;31(19):2412-22
pubmed: 21996734
Oncol Rep. 2015 Dec;34(6):2969-76
pubmed: 26397184
J Control Release. 2015 Dec 28;220(Pt B):727-37
pubmed: 26390807
Cancer Chemother Pharmacol. 2021 Dec;88(6):1021-1031
pubmed: 34599680
PLoS One. 2017 Jul 27;12(7):e0182039
pubmed: 28750018
Cancer Biol Ther. 2016 Oct 2;17(10):1062-1069
pubmed: 27611932
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33
pubmed: 15381773
Cell Biol Int. 2014 Sep;38(9):1076-9
pubmed: 24798520
Sci Rep. 2019 Nov 11;9(1):16497
pubmed: 31712601
Oncotarget. 2014 Jun 30;5(12):4180-94
pubmed: 24952704
Biochem Pharmacol. 2022 Apr;198:114954
pubmed: 35167807
J Bone Miner Res. 2018 Mar;33(3):517-533
pubmed: 29091316
Nature. 2015 Nov 26;527(7579):472-6
pubmed: 26560033
Int J Cell Biol. 2012;2012:317645
pubmed: 22496691
Mod Pathol. 2009 Sep;22(9):1139-50
pubmed: 19525928
Oncotarget. 2016 Aug 16;7(33):53254-53268
pubmed: 27449101
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
PLoS One. 2013 Oct 24;8(10):e76520
pubmed: 24204633
Mol Cancer Ther. 2005 Oct;4(10):1595-604
pubmed: 16227410
Cell Rep. 2021 Feb 9;34(6):108726
pubmed: 33567287
Oncogene. 2018 Feb 15;37(7):873-883
pubmed: 29059160
J Extracell Vesicles. 2015 Sep 16;4:26166
pubmed: 26385657
Int J Mol Sci. 2017 Jan 14;18(1):
pubmed: 28098816
J Bone Miner Res. 2020 Feb;35(2):396-412
pubmed: 31610048
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Cancer Lett. 2019 Jan;440-441:156-167
pubmed: 30336197
J Clin Invest. 2016 Apr 1;126(4):1190-7
pubmed: 27035810
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
J Cell Physiol. 2022 Jan;237(1):911-933
pubmed: 34463962
Neuropsychopharmacology. 2020 May;45(6):1050-1058
pubmed: 31986519
J Cell Physiol. 2012 Feb;227(2):658-67
pubmed: 21465472
Oncogene. 2010 Sep 2;29(35):4947-58
pubmed: 20562913
FEBS Open Bio. 2014 May 09;4:458-67
pubmed: 24918061
Front Oncol. 2013 May 16;3:120
pubmed: 23720710
Cell. 2014 Oct 23;159(3):499-513
pubmed: 25417103
Cancer Lett. 2019 Jul 10;454:37-43
pubmed: 30978440
Oncogene. 2013 May 16;32(20):2592-600
pubmed: 22777349
Mol Med Rep. 2013 Oct;8(4):1272-8
pubmed: 23969721
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Cancer Cell Int. 2018 Oct 22;18:164
pubmed: 30377411
Front Microbiol. 2016 Dec 15;7:1981
pubmed: 28018313
Nat Commun. 2021 Jan 11;12(1):213
pubmed: 33431899
Genes Dis. 2020 Jul 18;8(3):287-297
pubmed: 33997176
Gene. 2017 Aug 5;623:5-14
pubmed: 28438694
J Thorac Oncol. 2011 Dec;6(12):1984-92
pubmed: 22088988
Traffic. 2010 May;11(5):675-87
pubmed: 20136776
N Engl J Med. 2016 Sep 15;375(11):1044-53
pubmed: 27626518
Breast Cancer Res Treat. 2014 Sep;147(2):423-31
pubmed: 25007959
Cell Cycle. 2015 Aug 3;14(15):2473-83
pubmed: 26091251
Chemotherapy. 2017;62(1):43-53
pubmed: 27322648
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Leuk Lymphoma. 2012 Feb;53(2):315-22
pubmed: 21864037
Cell Metab. 2018 Dec 4;28(6):848-865.e6
pubmed: 30174307
Vascul Pharmacol. 2016 Nov;86:64-70
pubmed: 27013016
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41
pubmed: 21873242
J Clin Pathol. 2018 Feb;71(2):110-116
pubmed: 28942428
Arch Toxicol. 2017 Jul;91(7):2515-2538
pubmed: 28175954
Oncotarget. 2016 Sep 13;7(37):59173-59188
pubmed: 27385095
Cancers (Basel). 2016 Dec 09;8(12):
pubmed: 27941677
Mol Cell Biol. 2021 Apr 22;41(5):
pubmed: 33722958
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):786-91
pubmed: 21187392
Front Oncol. 2021 Sep 20;11:722922
pubmed: 34616676
Biochem Biophys Res Commun. 2012 Jan 13;417(2):679-85
pubmed: 22166209
Cell Res. 2016 Jun;26(6):713-27
pubmed: 27167569
Theranostics. 2022 Jan 9;12(4):1557-1569
pubmed: 35198057
Trends Biochem Sci. 1995 Oct;20(10):426-30
pubmed: 8533157
Front Cell Dev Biol. 2019 Jan 29;7:4
pubmed: 30761299
Mol Oncol. 2021 Dec;15(12):3430-3446
pubmed: 34213835
Cancer Res. 2005 Dec 1;65(23):10952-8
pubmed: 16322243
Front Immunol. 2019 Aug 08;10:1901
pubmed: 31440259
Cancers (Basel). 2020 Dec 14;12(12):
pubmed: 33327542
Hum Pathol. 2015 Nov;46(11):1752-9
pubmed: 26363527
Int J Cancer. 2002 Feb 20;97(6):751-60
pubmed: 11857350